This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Trading Biotech With Options: Exelixis

Stocks in this article: EXEL

I expect Exelixis shares to continue trading between $4 and $6 (but mostly around or below $5) before November expiration (Nov. 17) due to the back-and-forth selling and buying pressure between underwater shareholders, convertible bondholders and new speculators.

Investors can take advantage of this Exelixis situation by executing the following options trade:

Sell (10) NOV 4.0 strike Puts at 0.35 = $(350)
Buy 10 NOV 4.0 strike Calls at 0.75 = $750
Sell (20) NOV 5.0 strike Calls at 0.30 = $(600)
Buy 10 NOV 6.0 strike Calls at 0.15 = $150

Trade Initial P&L = $(50) Credit

This is a Credit Call Butterfly -- that is, I am actually being paid to put on this position (not much, $50 for this size, but still being paid nevertheless.) The position involves buying a Call Butterfly (see above) and selling a Put to fully finance the cost. The key risk is obviously to the downside since we sold the Put. Unless negative data comes out prior to November option expiration -- or the company unexpectedly announces a delay or other negative news -- I would expect Exelixis' share price to remain above $4 given the impending Nov. 29 FDA drug approval decision date.

Obviously, I could be wrong. Maximum profit for this trade size is $1,050 if the shares trade to $5 by expiration and this profit tapers off between $4 and $6. (See the P&L diagram.)

If the stock trades below $4 by Nov. 17 expiration I will be assigned the shares (1,000 shares for this size trade) and be positioned to either hold into the possible run-up, sell 4.0 strike DEC Calls against the shares (i.e. trade into a covered Call) or simply remove any risk and sell them.

Pelz is currently long Exelixis shares.

Follow Tony Pelz on Twitter.

Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of PelzOptions.com. Pelz currently resides in Denver, Colorado where he trades for his own account.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs